Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA + Anastrozole in Pre-operative HR+/HER2- Early Breast Cancer
NCT04113863Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tretinoin in breast cancer (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Proportion of complete BC cells cycle arrest (Ki67 < 2.7%) at 4 weeks. Started Jun 2019; status: terminated.
02
Drugs
tretinoin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04113863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113863.